Quest Diagnostics Files 8-K on Financials

Ticker: DGX · Form: 8-K · Filed: 2024-10-22T00:00:00.000Z

Sentiment: neutral

Topics: financial-reporting, 8-K

Related Tickers: DGX

TL;DR

Quest Diagnostics filed an 8-K for financial reporting. No major news.

AI Summary

Quest Diagnostics Inc. filed an 8-K on October 22, 2024, reporting on its results of operations and financial condition, as well as filing financial statements and exhibits. The filing does not appear to contain specific financial figures or significant operational updates beyond the standard reporting requirements.

Why It Matters

This filing indicates Quest Diagnostics is adhering to its reporting obligations, providing investors with updated financial information and disclosures.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for financial reporting and does not disclose any new material risks or events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Quest Diagnostics Inc.'s Results of Operations and Financial Condition, and to file Financial Statements and Exhibits.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported in this filing is October 22, 2024.

What is the company's state of incorporation?

Quest Diagnostics Inc. is incorporated in Delaware.

What is the company's principal executive office address?

The company's principal executive office is located at 500 Plaza Drive, Secaucus, NJ 07094.

Does this filing indicate any specific new business developments or material events?

This filing, as presented, indicates routine reporting on financial condition and results of operations, and does not explicitly detail any new specific business developments or material events beyond standard disclosure requirements.

From the Filing

0001022079-24-000187.txt : 20241022 0001022079-24-000187.hdr.sgml : 20241022 20241022064800 ACCESSION NUMBER: 0001022079-24-000187 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20241022 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241022 DATE AS OF CHANGE: 20241022 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 241384642 BUSINESS ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 BUSINESS PHONE: 9735202700 MAIL ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 8-K 1 dgx-20241022.htm 8-K dgx-20241022 0001022079 false 0001022079 2024-10-22 2024-10-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported) : October 22, 2024 Quest Diagnostics Inc orporated (Exact Name of Registrant as Specified in Its Charter) Delaware (State or other jurisdiction of incorporation) 001-12215 16-1387862 (Commission File Number) (I.R.S. Employer Identification No.) 500 Plaza Drive Secaucus, NJ 07094 (Address of principal executive offices) (Zip Code) (973) 520-2700 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value DGX New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).     Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02. Results of Operations and Financial Condition On October 22, 2024, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended September 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.      Item 9.01. Financial Statements and Exhibits d. Exhibit 99.1 Press release of Quest Diagnostics Incorporated dated October 22, 2024, announcing, among other things, its results for the quarter ended September 30, 2024. 104 The cover page from this current report on Form 8-K, formatted in Inline XBRL. Signature      Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be

View on Read The Filing